{"id":"https://openalex.org/W4282053318","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.9561","title":"A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 na\u00efve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.","display_name":"A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 na\u00efve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.","publication_year":2022,"publication_date":"2022-06-01","ids":{"openalex":"https://openalex.org/W4282053318","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.9561"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.16_suppl.9561","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.9561","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.9561","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087859996","display_name":"Brian Gastman","orcid":"https://orcid.org/0000-0003-2691-3409","observed_orcids":["https://orcid.org/0000-0003-2691-3409"]},"institutions":[{"id":"https://openalex.org/I36373038","display_name":"Cleveland Clinic Lerner College of Medicine","ror":"https://ror.org/02x4b0932","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750","https://openalex.org/I36373038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian Gastman","raw_affiliation_strings":["Cleveland Clinic Lerner College of Medicine, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Lerner College of Medicine, Cleveland, OH;","institution_ids":["https://openalex.org/I36373038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023766816","display_name":"Steven P. Fling","orcid":"https://orcid.org/0000-0001-6263-0153","observed_orcids":["https://orcid.org/0000-0001-6263-0153"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Fling","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA;","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080536692","display_name":"George Ansstas","orcid":"https://orcid.org/0000-0002-7178-8777","observed_orcids":["https://orcid.org/0000-0002-7178-8777"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George Ansstas","raw_affiliation_strings":["Washington University School of Medicine in St. Louis, St. Louis, MO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Washington University School of Medicine in St. Louis, St. Louis, MO;","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057402683","display_name":"Pauline Funchain","orcid":"https://orcid.org/0000-0002-7568-8626","observed_orcids":["https://orcid.org/0000-0002-7568-8626"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pauline Funchain","raw_affiliation_strings":["Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Foundation - Taussig Cancer Institute, Cleveland, OH;","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041474007","display_name":"Ann Willman Silk","orcid":"https://orcid.org/0000-0003-3877-3984","observed_orcids":["https://orcid.org/0000-0003-3877-3984"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann W. Silk","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024343002","display_name":"Philip Adam Friedlander","orcid":"https://orcid.org/0000-0001-6538-1615","observed_orcids":["https://orcid.org/0000-0001-6538-1615"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip Adam Friedlander","raw_affiliation_strings":["Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY;","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029588412","display_name":"Brendan D. Curti","orcid":"https://orcid.org/0000-0003-3948-2708","observed_orcids":["https://orcid.org/0000-0003-3948-2708"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brendan D. Curti","raw_affiliation_strings":["Portland Providence Medical Center, Portland, OR;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Portland Providence Medical Center, Portland, OR;","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076331659","display_name":"Yan Xing","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yan Xing","raw_affiliation_strings":["City of Hope Comprehensive Cancer Center, Duarte, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope Comprehensive Cancer Center, Duarte, CA;","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Oanh Nguyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Oanh Nguyen","raw_affiliation_strings":["NeoImmuneTech, Inc., Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeoImmuneTech, Inc., Rockville, MD;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ann Christensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Christensen","raw_affiliation_strings":["Neoimmunetech, Inc., Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neoimmunetech, Inc., Rockville, MD;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016887010","display_name":"Sara Ferrando\u2010Mart\u00ednez","orcid":"https://orcid.org/0000-0003-0721-555X","observed_orcids":["https://orcid.org/0000-0003-0721-555X"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Ferrando-Martinez","raw_affiliation_strings":["NeoImmuneTech, Inc., Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeoImmuneTech, Inc., Rockville, MD;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5104236620","display_name":"Andreanne M. Lacroix","orcid":"https://orcid.org/0009-0005-5358-8922","observed_orcids":["https://orcid.org/0009-0005-5358-8922"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andreanne Lacroix","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA;","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004786915","display_name":"Byung Ha Lee","orcid":"https://orcid.org/0000-0002-4139-1226","observed_orcids":["https://orcid.org/0000-0002-4139-1226"]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Byung Ha Lee","raw_affiliation_strings":["NeoImmuneTech, Inc., Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeoImmuneTech, Inc., Rockville, MD;","institution_ids":["https://openalex.org/I4405267539"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087891557","display_name":"David Michael Miller","orcid":"https://orcid.org/0000-0001-9736-9119","observed_orcids":["https://orcid.org/0000-0001-9736-9119"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David M. Miller","raw_affiliation_strings":["Massachusetts General Hospital, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075566772","display_name":"Jeffrey Alan Sosman","orcid":"https://orcid.org/0000-0002-0650-9698","observed_orcids":["https://orcid.org/0000-0002-0650-9698"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4210147348","display_name":"Northwestern Medicine","ror":"https://ror.org/04fzwnh64","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey A. Sosman","raw_affiliation_strings":["Northwestern University Medical Center, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwestern University Medical Center, Chicago, IL;","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4210147348"]}]},{"author_position":"last","author":{"id":null,"display_name":"Jean Fan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267539","display_name":"NeoImmuneTech, Inc. (United States)","ror":"https://ror.org/035t43f61","country_code":"US","type":"company","lineage":["https://openalex.org/I4405267539"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Fan","raw_affiliation_strings":["NeoImmuneTech, Inc., Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"NeoImmuneTech, Inc., Rockville, MD;","institution_ids":["https://openalex.org/I4405267539"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"16_suppl","first_page":"9561","last_page":"9561"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11306","display_name":"Nonmelanoma Skin Cancer Studies","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.8859999775886536},{"id":"https://openalex.org/keywords/interleukin-7","display_name":"IL-7","score":0.7860000133514404},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.6990000009536743},{"id":"https://openalex.org/keywords/high-risk-skin-cancer","display_name":"high-risk skin cancer","score":0.722000002861023},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8169999718666077},{"id":"https://openalex.org/keywords/merkel-cell-carcinoma","display_name":"Merkel cell carcinoma","score":0.9850000143051147},{"id":"https://openalex.org/keywords/cutaneous-squamous-cell-carcinoma","display_name":"cutaneous squamous cell carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/relapsed-refractory-cancer","display_name":"relapsed/refractory cancer","score":0.8259999752044678},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9279999732971191},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8880000114440918},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8109999895095825},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7390000224113464},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6520000100135803}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8902006149291992},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.7825700044631958},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5703773498535156},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5425442457199097},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5289922952651978},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5051069855690002},{"id":"https://openalex.org/C2778342957","wikidata":"https://www.wikidata.org/wiki/Q1711744","display_name":"Merkel cell carcinoma","level":3,"score":0.4924241006374359},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.46622657775878906},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.4219765365123749},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.36972254514694214},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3450104594230652},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.32252517342567444},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.2678276300430298},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.16_suppl.9561","doi":"https://doi.org/10.1200/jco.2022.40.16_suppl.9561","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.16_suppl.9561","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3170154951","https://openalex.org/W4251554516","https://openalex.org/W4286296206","https://openalex.org/W4308396192","https://openalex.org/W3213578504","https://openalex.org/W3213263579","https://openalex.org/W4399662697","https://openalex.org/W4415699979","https://openalex.org/W3083055113","https://openalex.org/W4311146655"],"abstract_inverted_index":{"9561":[0],"Background:":[1],"Novel":[2],"immunotherapy":[3],"approaches":[4],"have":[5,48],"changed":[6],"the":[7,30,61,72,82,97,162,172,175,319,350,364,372,394,408,449,457,476],"treatment":[8],"landscape":[9],"of":[10,33,65,101,161,190,244,281,329,349,374,377,393,433,456],"patients":[11],"(pts)":[12],"with":[13,77,105,109,225,336,452],"high-risk":[14,85,115,423],"cancers":[15,425],"like":[16],"melanoma,":[17],"Merkel":[18],"cell":[19,25,396],"carcinoma":[20,26],"(MCC)":[21],"and":[22,63,70,99,144,153,174,184,213,236,241,259,270,318,340,356,363,389,415,435,440,448,469,484,486,491],"cutaneous":[23],"squamous":[24],"(cSCC).":[27],"However,":[28],"despite":[29],"widespread":[31],"use":[32],"checkpoint":[34],"inhibitors":[35],"(CPI)":[36],"in":[37,67,75,84,103,107,126,198,229,233,238,300,305,385,420,427,481],"these":[38],"indications,":[39],"most":[40,386],"pts":[41,108,128,195,289,314],"either":[42],"fail":[43],"to":[44,95,166,344],"respond":[45],"or":[46,112,147],"eventually":[47],"progressed.":[49],"NT-I7":[50,74,102,131,282,346,434,443],"(efineptakin":[51],"alfa)":[52],"is":[53,90,407],"a":[54,91,123,252,382,390,453,460],"long-acting":[55],"human":[56],"IL-7":[57,412],"that":[58],"can":[59],"increase":[60,365],"number":[62,243],"functionality":[64],"T-cells":[66,358],"peripheral":[68],"blood":[69],"within":[71],"tumors.":[73],"combination":[76,104,432],"atezolizumab":[78],"(atezo),":[79],"may":[80],"augment":[81],"efficacy":[83,100,470],"skin":[86,116,424],"cancers.":[87,117],"Methods:":[88],"This":[89,405],"phase":[92,163,177,199,478],"1b/2a":[93],"study":[94],"evaluate":[96,167],"safety":[98,439,468],"atezo":[106,154,284,436],"CPI-":[110],"na\u00efve":[111],"relapsed/refractory":[113],"(R/R)":[114],"Phase":[118],"1b":[119,164],"dose":[120,139,179,333,362],"escalation":[121],"followed":[122],"3+3":[124],"design,":[125],"which":[127],"who":[129],"received":[130],"IM":[132],"every":[133],"3":[134,138,239,331],"weeks":[135],"(Q3W)":[136],"at":[137,149,254,268,338,402],"levels":[140],"(DL1-3):":[141],"120,":[142],"360,":[143],"840":[145],"\u00b5g/kg":[146,279],"Q6W":[148,280],"DL4":[150,214,269],"1200":[151,156,278,285],"\u00b5g/kg,":[152],"IV":[155],"mg":[157,286],"Q3W.":[158,287],"The":[159,218,275,431],"objectives":[160],"were":[165,196,266,296,308],"dose-limiting":[168],"toxicity":[169],"(DLT),":[170],"determine":[171],"MTD":[173,271],"recommended":[176],"2":[178,237,299],"(RP2D),":[180],"pharmacokinetics":[181],"(PK),":[182],"pharmacodynamics":[183],"preliminary":[185],"antitumor":[186,465],"activity.":[187,442,466],"Results:":[188],"As":[189],"January":[191],"14,":[192],"2022,":[193],"16":[194],"enrolled":[197],"1b:":[200],"DL1":[201],"(n":[202,206,210,215],"=":[203,207,211,216],"3),":[204,208],"DL2":[205],"DL3":[209,255],"7),":[212],"3).":[217],"median":[219,242],"age":[220],"was":[221,272,277,323,366],"66":[222],"years":[223],"[46-86],":[224],"ECOG":[226],"PS":[227],"0":[228],"6":[230],"(37%),":[231],"1":[232,247],"7":[234],"(44%)":[235],"(19%),":[240],"prior":[245],"therapies":[246],"[1-2].":[248],"One":[249],"pt":[250],"had":[251,290,315],"DLT":[253],"[Grade":[256],"(G)3":[257],"confusion":[258],"G3":[260],"increased":[261,445],"AST]":[262],"but":[263],"no":[264,309],"DLTs":[265],"reported":[267],"not":[273],"reached.":[274],"RP2D":[276],"plus":[283],"All":[288],"drug":[291],"related":[292,310],"AEs.":[293,312],"Most":[294],"AEs":[295],"G":[297],"1-":[298],"11(69%)":[301],"pts;":[302],"5":[303],"(31%)":[304],"G3.":[306],"There":[307],"G4/G5":[311],"Eleven":[313],"stable":[316],"disease":[317,320],"control":[321],"rate":[322],"69%":[324],"(11/16).":[325],"Preliminary":[326],"PK":[327],"analysis":[328],"DL1-":[330],"showed":[332,381,437],"dependent":[334],"Cmax,":[335],"Tmax":[337],"\u030324hr":[339],"T\u00bd":[341],"ranging":[342],"\u030375hr":[343],"125hr.":[345],"dose-dependent":[347],"expansion":[348,384,392,455],"absolute":[351],"lymphocyte":[352,447],"count,":[353],"CD3+,":[354],"CD4+":[355],"CD8+":[357,398,458],"peaked":[359],"after":[360],"one":[361],"maintained":[367],"by":[368,475],"repeat":[369],"dosing":[370],"until":[371],"end":[373],"treatment.":[375],"Immunophenotyping":[376],"memory":[378,397],"T-cell":[379,387,399,450],"subsets":[380,388],"5-fold":[383],"30-fold":[391],"stem":[395],"subset":[400],"(Tscm)":[401],"DL4.":[403],"Conclusions:":[404],"trial":[406,480,494],"first":[409],"time":[410],"an":[411],"cytokine-based":[413],"therapy":[414],"CPI":[416,487],"has":[417],"been":[418],"assessed":[419],"UV":[421],"induced":[422],"including":[426],"IO":[428],"refractory":[429],"pts.":[430],"favorable":[438],"anticancer":[441],"significantly":[444],"total":[446],"compartment,":[451],"greatest":[454],"Tscm,":[459],"vital":[461],"population":[462],"for":[463],"eliciting":[464],"Additional":[467],"updates":[471],"will":[472],"be":[473],"provided":[474],"ongoing":[477],"2a":[479],"CPI-na\u00efve":[482],"cSCC":[483,490],"MCC":[485],"R/R":[488],"MCC,":[489],"melanoma.":[492],"Clinical":[493],"information:":[495],"NCT03901573.":[496]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-06-13T00:00:00"}